Fineline Cube

Follow:
14435 Articles
Vigonvita's Simenafil Receives NMPA Approval for Erectile Dysfunction Treatment
CompanyDrug

Vigonvita’s Simenafil Receives NMPA Approval for Erectile Dysfunction Treatment

Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development
CompanyDeals

Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development

Otsuka to Acquire Cantargia's IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases
CompanyDeals

Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases

Huadong Medicine Receives FDA Approval for Clinical Trials of Innovative ADC HDM2020
CompanyDrug

Huadong Medicine Receives FDA Approval for Clinical Trials of Innovative ADC HDM2020

Ningbo Health Gene and Biofast Biotech Partner to Advance Genetic Testing for Hereditary Diseases
CompanyDeals

Ningbo Health Gene and Biofast Biotech Partner to Advance Genetic Testing for Hereditary Diseases

Boehringer Ingelheim Licenses Spevigo to LEO Pharma for Global Dermatology Expansion
CompanyDeals

Boehringer Ingelheim Licenses Spevigo to LEO Pharma for Global Dermatology Expansion

Peijia Medical Completes First Patient Implantation for MonarQ TTVR System in Global Clinical Study
CompanyMedical Device

Peijia Medical Completes First Patient Implantation for MonarQ TTVR System in Global Clinical Study

Golden Age Health Secures Exclusive Rights to Innostellar's Gene Therapy LX-101 in China
CompanyDeals

Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China

Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527
CompanyDrug

Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527

China Medical System's CMS-D001 Gains NMPA Approval for Atopic Dermatitis Trials
CompanyDrug

China Medical System’s CMS-D001 Gains NMPA Approval for Atopic Dermatitis Trials

NHSA Reports 2024 Healthcare Stats: BMI Fund Reaches RMB 3.49 Trillion Income with 95% Participation Rate
Policy / Regulatory

NHSA Reports 2024 Healthcare Stats: BMI Fund Reaches RMB 3.49 Trillion Income with 95% Participation Rate

SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data
CompanyDrug

SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data